Immune Thrombocytopenia

The FDA granted fast track designation to rilzabrutinib for treatment of immune thrombocytopenia, according to the agent’s manufacturer.

The FDA granting orphan drug designation to a pancreatic cancer product was one of the top stories in hematology and oncology last week.

ORLANDO — ASH named three Choosing Wisely Champions today at its Annual Meeting and Exposition, recognizing clinicians who have implemented projects to improve quality and reduce costs at their institutions.